Clinical trials
Primary Breast Cancer clinical trials
Below are recruiting primary breast cancer clinical trials, each written for real people, not researchers. We’re tracking 711 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07312786Recruiting
Virtual app for breast and colorectal cancer survivors
This study tests if a virtual app can help people who have finished treatment for breast or colorectal cancer feel supported and stay healthy. It looks at whether using the app is easy and helpful for cancer survivors.
Saint John, New BrunswickAges 18 years+ - NCT05465031RecruitingPhase 4
Testing heart-protection medicine during breast cancer treatment
This trial tests sacubitril/valsartan to help prevent heart weakness (cardiotoxicity) caused by breast cancer treatments like anthracyclines and/or anti-HER2 drugs. If you qualify, you may be offered this heart-protection medicine while your cancer is treated.
Opole, Opole VoivodeshipAges 18 years+ - NCT07297134Recruiting
PTEN and Organ-Specific microRNAs in Breast Cancer
This trial looks at specific molecules (PTEN and microRNAs) in the blood to see if they help doctors understand how breast cancer spreads. If you have breast cancer (whether it has spread or not) or are healthy, you might be eligible.
Istanbul, IstanbulAges 18 years+ - NCT07304934Recruiting
New blood test model to check lymph node status in breast cancer
This study uses a blood test and imaging to predict whether breast cancer has spread to underarm lymph nodes, helping guide surgery. It may reduce unnecessary lymph node removal.
Hangzhou, ZhejiangAges 18 years+ - NCT07292571Enrolling by invitationPhase 2
Tracing breast cancer HER2 with a special scan
This study uses a radioactive tracer to see how much HER2 protein is on your breast cancer cells. The scan may help doctors understand the type of HER2 you have and choose the best treatment.
TomskAges 18–80 - NCT07281833RecruitingPhase 3
Testing capivasertib with hormone therapy for advanced breast cancer
This trial tests a new oral drug called capivasertib combined with standard hormone therapy for people with advanced breast cancer that is HR-positive and HER2-negative. It is for those whose cancer has progressed on previous hormone therapy and who have a specific gene change (PIK3CA, AKT1, or PTEN).
AnderlechtAges 18 years+ - NCT05485766RecruitingPhase 2
Pembrolizumab with cancer medicines for BRCA-mutated triple negative breast cancer
This Phase 2 trial studies a treatment plan given before surgery (neoadjuvant) and after surgery (adjuvant) for people with BRCA1/2-mutated triple negative breast cancer that has not spread. It aims to improve how well the cancer responds and how long people stay cancer-free.
Gifu, GifuAges 18 years+ - NCT07273357Recruiting
CDK4/6 inhibitors for older breast cancer patients
This study looks at how well older breast cancer patients (70 years and older) do when treated with a type of drug called a CDK4/6 inhibitor along with hormone therapy after surgery. The goal is to use simple health checks to help doctors decide if this treatment is right for you.
GävleAges 70 years+ - NCT07274852RecruitingPhase 1
Study of a radioactive drug for advanced solid tumors
This trial tests a new radioactive drug (177Lu-BL-ARC001) for people with advanced lung, breast, head and neck, or other solid tumors that have not responded to standard treatments. It aims to see if the drug can target and shrink tumors while limiting side effects.
Chengdu, SichuanAges 18 years+ - NCT07275463Enrolling by invitationPhase 2
Study of DB8 imaging in estrogen receptor positive and negative breast cancer
This trial uses a special imaging agent called DB8 to see how it builds up in breast tumors. It compares results between women with estrogen receptor-positive and estrogen receptor-negative cancers to help improve detection.
TomskAges 18–80 - NCT07251868Recruiting
Study of SG in breast cancer with brain metastases
This study follows patients with breast cancer that has spread to the brain and who have already received the drug Sacituzumab Govitecan (SG). The goal is to learn how well SG works in real-world settings and to see how patients are doing over time.
Beijing, Beijing MunicipalityAges 18 years+ - NCT06006806Recruiting
Proton therapy skin effects study for breast cancer
This study looks at how proton therapy affects the skin in people being treated for early-stage breast cancer. It aims to understand skin reactions better so doctors can reduce side effects.
Knoxville, TennesseeAges 18 years+ - NCT07220135RecruitingPhase 2
Comparing two drug combos before surgery for HER2+ breast cancer
This trial tests two different combinations of chemotherapy and targeted therapy given before surgery for HER2-positive breast cancer. The goal is to see which combination works better at shrinking the tumor.
Fairway, KansasAges 18 years+ - NCT04933266Recruiting
Nerve block plan for breast surgery
This trial studies a type of pain-control injection (a nerve block) to help with anesthesia during breast cancer surgery. It may help improve comfort and reduce pain around the operation.
Sheung Shui, New TerritoriesAges 18–80 - NCT07205822RecruitingPhase 3
Dato-DXd for advanced HR-positive, HER2-low breast cancer
This trial tests a new drug called Dato-DXd for people with a certain type of advanced breast cancer that has stopped responding to hormone therapy. The drug targets a protein on cancer cells to help stop the cancer from growing.
Largo, FloridaAges 18 years+ - NCT06938360Recruiting
Breast-conserving surgery for central breast cancer study
This trial compares breast-conserving surgery (removing only the tumor and nearby tissue) to total mastectomy (removing the whole breast) for women with breast cancer in the central area of the breast. The goal is to see if the less extensive surgery works just as well.
Xi'an, ShaanxiAges 18–70 - NCT07195227RecruitingPhase 2
Camizestrant plus ribociclib for advanced breast cancer
This trial tests a combination of two drugs, camizestrant and ribociclib, for people with a certain type of advanced breast cancer (HR+/HER2-). It is for those whose cancer has grown or spread despite previous hormone therapy. The goal is to see if this new combination can help control the cancer.
DessauAges 18 years+ - NCT07198724RecruitingPhase 1/Phase 2
A study of elacestrant plus Enhertu for advanced breast cancer
This trial tests a new combination of two targeted drugs (elacestrant and Enhertu) for people with a specific type of advanced breast cancer (HR-positive, HER2-low or ultra-low) that did not respond to standard treatments like CDK4/6 inhibitors. The goal is to see if this combination works better than current options.
Boston, MassachusettsAges 18 years+ - NCT07190469RecruitingPhase 1
PQ203 for advanced solid tumors like triple-negative breast cancer
This early-phase trial tests a new drug called PQ203 for people with advanced solid tumors, including triple-negative breast cancer, that have stopped responding to standard treatments. It helps doctors learn whether the drug is safe and how it affects tumors.
Houston, TexasAges 18 years+ - NCT06225284RecruitingPhase 2
Chemotherapy with or without hormone drug for premenopausal TNBC
This trial tests whether adding a hormone-blocking drug (GnRH agonist) to standard chemotherapy before surgery helps premenopausal women with triple-negative breast cancer. It aims to improve treatment outcomes by targeting hormones that may fuel tumor growth.
TaipeiAges 18 years+ - NCT07179809Recruiting
Lifestyle program for women with metastatic breast cancer
This trial tests a group-based lifestyle program for women with HR+/HER2- metastatic breast cancer. The program helps you improve diet, increase physical activity, and learn mind-body practices in a supportive group setting.
Houston, TexasAges 18 years+ - NCT07179744Recruiting
Skipping radiation for low-risk node-positive breast cancer
This trial tests whether some women with low-risk breast cancer that has spread to a few lymph nodes can safely skip radiation therapy after surgery. It aims to reduce side effects while keeping the cancer from coming back.
Guangzhou, GuangdongAges 18–70 - NCT05658172Recruiting
Less vs more frequent follow-up after early breast cancer
This trial compares standard follow-up visits versus more intensive follow-up for people with early breast cancer after their main treatment. The goal is to see whether closer monitoring finds problems earlier or improves outcomes.
UlmAges 18–75 - NCT07159451RecruitingPhase 2
Elacestrant for premenopausal women with early breast cancer
This trial tests a new hormone therapy pill, elacestrant, given alone or with another drug to suppress ovarian function before surgery. It's for premenopausal women with early-stage, hormone receptor-positive, HER2-negative breast cancer to see if it can shrink the tumor.
VillejuifAges 18 years+
Hear when a new Primary Breast Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for primary breast cancer?
- Yes. Clin2 currently lists 711 recruiting primary breast cancer studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a primary breast cancer trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a primary breast cancer trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.